{"filing":{"accession_number":"0001213900-26-090748","cik":"0001514183","ticker":"SILO","company_name":"Silo Pharma, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-14","primary_document":"ea0302240-8k_silo.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026090748/ea0302240-8k_silo.htm"},"events":[{"id":28242,"run_id":25823,"accession_number":"0001213900-26-090748","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Silo Pharma held its annual shareholder meeting on August 14, 2026, with voting results on four proposals: election of four directors (all approved), ratification of Salberg \u0026 Company as auditor (approved), authorization to increase authorized common shares from 6.67 million to 250 million shares (approved with 498,224 votes for and 190,599 against), and meeting adjournment authority (approved). The substantial increase in authorized shares represents a material expansion of the company's equity issuance capacity and potential dilution.","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":30121,"accession_number":"0001213900-26-090748","item_number":"5.03","item_title":"Amendments","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure reports a shareholder-approved amendment to the Articles of Incorporation increasing authorized common shares from 6.67 million to 250 million shares. While a routine governance matter, the 37-fold increase in authorized shares is material to investors as it substantially expands the company's capacity for equity issuance and potential dilution, affecting shareholder interests and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:09:01.301717+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30122,"accession_number":"0001213900-26-090748","item_number":"5.07","item_title":"Submission of Matters to a Vote of","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Silo Pharma's annual shareholder meeting held on August 14, 2026. The filing presents voting outcomes for four proposals: director elections (all four nominees elected), auditor ratification (Salberg \u0026 Company approved), authorization to increase authorized common shares from 6.67M to 250M (approved), and meeting adjournment authority (approved). The material Common Stock Increase Proposal—a significant dilution authorization—passed with 498,224 votes for and 190,599 against, making this disclosure material to investors assessing capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:09:01.301717+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30121,"accession_number":"0001213900-26-090748","item_number":"5.03","item_title":"Amendments","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure reports a shareholder-approved amendment to the Articles of Incorporation increasing authorized common shares from 6.67 million to 250 million shares. While a routine governance matter, the 37-fold increase in authorized shares is material to investors as it substantially expands the company's capacity for equity issuance and potential dilution, affecting shareholder interests and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:09:01.301717+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-08-17"},{"id":30122,"accession_number":"0001213900-26-090748","item_number":"5.07","item_title":"Submission of Matters to a Vote of","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Silo Pharma's annual shareholder meeting held on August 14, 2026. The filing presents voting outcomes for four proposals: director elections (all four nominees elected), auditor ratification (Salberg \u0026 Company approved), authorization to increase authorized common shares from 6.67M to 250M (approved), and meeting adjournment authority (approved). The material Common Stock Increase Proposal—a significant dilution authorization—passed with 498,224 votes for and 190,599 against, making this disclosure material to investors assessing capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:09:01.301717+00:00","company_name":"Silo Pharma, Inc.","ticker":"SILO","filing_date":"2026-08-17"}]}